EUVIMEDEUVIMED entdecken
Crossref

PPARγ activation reduces pancreatic beta cell death in type 1 diabetes by decreasing heparanase-dependent insulitis

Qinyao Zhou, Meiwei Li, Jia Zhang, Xiaohang Zhou, Qi Zhu, Hailing Ni, Yourong Hu, Lei Wang, Yuting Ge, Kunxin Xie, Guanting Li, Yizheng Zhang und 4 weitere

International Immunopharmacology · 2025

DOI: 10.1016/j.intimp.2025.115183 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2025. Verfasst von Qinyao Zhou und 15 weiteren Autor:innen. Beteiligte Einrichtung: The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, Nanjing Medical University, Wuxi, C…. Hauptthemen laut MEDLINE: PPAR gamma, Diabetes Mellitus, Type 1, Insulin-Secreting Cells, Glucuronidase. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Jiangsu Province Natural Science Foundation, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

While the majority of individuals with type 1 diabetes (T1D) receives lifelong exogenous insulin replacement therapy, a clinically significant subset remains refractory to achieving optimal glycemic targets, necessitating the exploration of novel adjunctive medications to enhance T1D treatment strategies. The aim of this study was to explore the efficacy of rosiglitazone (ROZ), a typical thiazolidinedione as selective agonists of the peroxisome proliferator-activated receptor gamma (PPARγ), in the therapeutic management of T1D. The pharmacological effects of ROZ in different T1D mouse models induced by either multiple-low-dose (MLD) or single-high-dose (SHD) streptozotocin (STZ). Further morphological, bioinformatic, and in vitro experiments using cultured bone marrow-derived monocytes, were performed to explore the possible underlying mechanisms. In vivo findings revealed that ROZ primarily showed therapeutic effects in the MLD-STZ model, which is characterized by inflammatory damage to pancreatic beta cells, rather than SHD-STZ model. Mechanistically, PPARγ activation, mediated by ROZ, downregulates the macrophage expression of heparanase, a specific endoglycosidase of the glycosaminoglycan heparan sulfate. This downregulation inhibits the degradation of intra-islet extracellular heparan sulfate, thereby enhancing the integrity of the physical barrier within the islets. Consequently, PPARγ activation reduces the infiltration of inflammatory immune cells into the islets, thereby suppressing the damage to pancreatic beta cells associated with T1D. Our data emphasize the importance of sustained inflammation in the upregulation of heparanase in macrophages, while also underscoring the pivotal role played by the PPARγ-heparanase axis. This study provides novel evidence for the potential targeting of PPARγ-heparanase as an adjunctive treatment strategy for T1D.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PPAR gammaDiabetes Mellitus, Type 1Insulin-Secreting CellsGlucuronidaseDiabetes Mellitus, ExperimentalRosiglitazoneHypoglycemic AgentsAnimalsMiceMaleHumansMice, Inbred C57BLCell DeathMacrophagesStreptozocinHeparanase

Stichwörter der Autor:innen

HeparanaseMacrophagesPPARγPancreatic beta cellsType 1 diabetes

Substanzen

PPAR gammaGlucuronidaseRosiglitazoneHypoglycemic AgentsStreptozocinHeparanase

Autor:innen und Institutionen

  • The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, Nanjing Medical University, Wuxi, China; Key Laboratory of Human Functional Genomics of Jiangsu Province,…
  • Key Laboratory of Human Functional Genomics of Jiangsu Province, Department of Biochemistry and Molecular Biology, Nanjing Medical University, Nanjing, China.
  • National Demonstration Center for Experimental Basic Medical Education, Nanjing Medical University, Nanjing, China.
  • The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, Nanjing Medical University, Wuxi, China.
  • National Demonstration Center for Experimental Basic Medical Education, Nanjing Medical University, Nanjing, China. Electronic address: xinyuancao@njmu.edu.cn.
  • Key Laboratory of Human Functional Genomics of Jiangsu Province, Department of Biochemistry and Molecular Biology, Nanjing Medical University, Nanjing, China; Department of Endocrinology, the Third Affiliated Hospital w…

Förderung

  • Jiangsu Province Natural Science Foundation
  • National Natural Science Foundation of China

Zitieren

APA

Zhou, Q., Li, M., Zhang, J., Zhou, X., Zhu, Q., Ni, H., Hu, Y., Wang, L., Ge, Y., Xie, K., Li, G., Zhang, Y., Zhu, X., Cao, X., Han, X., & Sun, P. (2025). PPARγ activation reduces pancreatic beta cell death in type 1 diabetes by decreasing heparanase-dependent insulitis. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2025.115183

Vancouver

Zhou Q, Li M, Zhang J, Zhou X, Zhu Q, Ni H, et al. PPARγ activation reduces pancreatic beta cell death in type 1 diabetes by decreasing heparanase-dependent insulitis. International Immunopharmacology. 2025. doi:10.1016/j.intimp.2025.115183

BibTeX
@article{Zhou2025,
  author = {Zhou, Qinyao and Li, Meiwei and Zhang, Jia and Zhou, Xiaohang and Zhu, Qi and Ni, Hailing and Hu, Yourong and Wang, Lei and Ge, Yuting and Xie, Kunxin and Li, Guanting and Zhang, Yizheng and Zhu, Xiaowei and Cao, Xinyuan and Han, Xiao and Sun, Peng},
  title = {PPARγ activation reduces pancreatic beta cell death in type 1 diabetes by decreasing heparanase-dependent insulitis},
  journal = {International Immunopharmacology},
  year = {2025},
  doi = {10.1016/j.intimp.2025.115183}
}
Kostenlos starten →